Product image of Mayzent (Siponimod) supplied by GNH India

Mayzent

Active Ingredient:
Siponimod
Origin:
EU

Mayzent (Siponimod)

Siponimod, the active ingredient in Mayzent, is a sphingosine‑1‑phosphate (S1P) receptor modulator presented as a tablet for oral use. It treats relapsing forms of multiple sclerosis and secondary progressive multiple sclerosis in adults.

GNH India supplies Mayzent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Novartis Europharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Mayzent acts on the sphingosine‑1‑phosphate receptor pathway to modify disease activity in multiple sclerosis.
  • Relapsing‑remitting multiple sclerosis: reduces annualized relapse rate and slows disability accumulation.
  • Secondary progressive multiple sclerosis with active disease: delays worsening of disability.
  • Active disease in multiple sclerosis: decreases inflammatory activity as shown by MRI lesion reduction.

How It Works

  • Siponimod selectively binds to S1P1 and S1P5 receptors on lymphocytes, preventing their egress from lymph nodes. This reduces circulating lymphocyte counts and limits central nervous system inflammation, thereby modifying the disease course of multiple sclerosis.

Side Effects

Common Side Effects

  • Headache: mild to moderate intensity.
  • Hypertension: elevated blood pressure requiring monitoring.
  • Elevated liver enzymes: transient increases in ALT/AST.
  • Lymphopenia: reduced lymphocyte count.
  • Nasopharyngitis: upper respiratory tract infection symptoms.
  • Diarrhea: loose stools, usually self‑limiting.

Serious or Rare Side Effects

  • Severe infections: opportunistic infections requiring immediate medical attention.
  • Cardiac arrhythmia: conduction abnormalities, especially after first dose.
  • Macular edema: visual disturbances, ophthalmologic evaluation needed.
  • Progressive multifocal leukoencephalopathy (PML): rare but potentially fatal brain infection.
  • Severe liver injury: jaundice or hepatic failure signs.
  • Malignancy: increased risk of certain cancers with long‑term use.

Precautions & Warnings

  • Before initiating therapy, clinicians should assess baseline parameters and monitor patients regularly.
  • Monitor lymphocyte count: check before start and periodically during treatment.
  • Assess liver function: perform baseline and periodic ALT/AST tests.
  • Screen cardiac conduction: obtain ECG prior to first dose.
  • Avoid use in active infection: defer treatment until infection resolves.
  • Pregnancy and breastfeeding: discuss risks; drug not recommended.
  • Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Avoid Interactions

Siponimod may interact with several drug classes; careful review is required.

Major Interactions (Avoid)

  • Strong CYP2C9 inhibitors (e.g., fluconazole): may increase siponimod exposure.
  • CYP3A4 inducers (e.g., carbamazepine): may reduce efficacy.
  • Concurrent S1P modulators: additive immunosuppression risk.

Moderate Interactions (Monitor Closely)

  • Live vaccines: should be avoided during therapy.
  • Beta‑blockers: may affect heart‑rate monitoring after first dose.
  • Antihypertensives: monitor blood pressure for additive effects.

Frequently Asked Questions

Mayzent is prescribed to treat relapsing forms of multiple sclerosis and secondary progressive multiple sclerosis with active disease. It helps reduce relapse frequency, slows disability progression, and limits inflammatory activity in the central nervous system.

Siponimod selectively modulates sphingosine‑1‑phosphate receptors 1 and 5, preventing lymphocytes from leaving lymph nodes. This lowers circulating immune cells, reducing central nervous system inflammation that drives multiple sclerosis activity.

The dosage of Mayzent is individualized by the prescribing clinician based on the patient’s medical condition, weight, and response. The prescriber determines the appropriate starting dose and any subsequent titration.

Safety data for Siponimod in pregnancy and lactation are limited. It is generally not recommended for use in pregnant or breastfeeding women unless the potential benefit justifies the potential risk. Consultation with a healthcare professional is essential.

To request Mayzent, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mayzent belongs to the S1P receptor modulator class, offering oral administration and a selective receptor profile (S1P1/S1P5). Compared with broader S1P modulators, it may have a different safety and efficacy balance, but choice of therapy depends on individual patient factors and physician judgment.

Mayzent tablets should be stored at ambient temperature below 25 °C, in the original blister pack, and protected from moisture and direct sunlight. Do not refrigerate or freeze the product.

Mayzent is taken orally as a tablet, usually with water. The exact dosing schedule, including any titration steps, is determined by the prescribing clinician and should be followed exactly as instructed.

Serious risks include severe infections, cardiac conduction abnormalities (especially after the first dose), macular edema, progressive multifocal leukoencephalopathy (PML), severe liver injury, and potential increased risk of malignancies. Patients should be monitored closely for these events.

Mayzent is contraindicated in patients with known hypersensitivity to siponimod, those with certain cardiac conditions (e.g., recent myocardial infarction, uncontrolled arrhythmias), severe liver impairment, and individuals currently receiving live vaccines. A thorough medical assessment is required before initiation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Siponimod

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT